Press Releases May 15, 2026 08:00 AM

Dycom Industries, Inc. to Host Fiscal 2027 First Quarter Results Call on May 27, 2026

Dycom Industries Announces Date and Details for Fiscal 2027 Q1 Earnings Call

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
DY

Dycom Industries, Inc., a leading specialty contracting service provider in telecommunications and utilities, announced it will hold its fiscal 2027 first quarter earnings call on May 27, 2026. A press release with the quarter's financial results will be issued earlier that day, followed by a conference call and webcast to discuss performance and answer investor questions.

Dycom Industries, Inc. to Host Fiscal 2027 First Quarter Results Call on May 27, 2026
DY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Dycom will release fiscal 2027 Q1 financial results on May 27, 2026, followed by a conference call and webcast.
  • The company provides specialty contracting services including telecommunications infrastructure and utility industries across the U.S.
  • Investor engagement is encouraged through a Q&A session accessible by registration, enhancing transparency.

WEST PALM BEACH, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- Dycom Industries, Inc. (NYSE: DY) will host a conference call to discuss fiscal 2027 first quarter results on Wednesday, May 27, 2026, at 9:00 a.m. ET. Dycom will issue a press release reporting its results earlier that morning.

Interested parties may participate in the question and answer session of the conference call by registering at https://register-conf.media-server.com/register/BIc988a8ba8b25404b95f6070d40129047. Upon registration, participants will receive a dial-in number and unique PIN to access the call. Participants are encouraged to join approximately ten minutes prior to the scheduled start time.

For all other attendees, a live listen-only audio webcast of the call, including an accompanying slide presentation, can be accessed directly at https://edge.media-server.com/mmc/p/yago4jtm. A replay of the live webcast and the related materials will be available on the Company’s Investor Center website at https://ir.dycomind.com for approximately 120 days following the event.

About Dycom Industries, Inc.
Dycom is a leading provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. These services include program management, planning, engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications providers. Additionally, Dycom provides electrical contracting services for data centers and other vital industries, underground facility locating services for various utilities, including telecommunications providers, as well as other construction and maintenance services for electric and gas utilities.

For more information, contact:
Callie Tomasso, Vice President Investor Relations & Corporate Communications
Email: investorrelations@dycomind.com 
Phone: (561) 627-7171


Risks

  • Financial and operational risks dependent on telecommunications and utility industry demand and infrastructure spending.
  • Potential market volatility around earnings release may affect stock price temporarily.
  • Execution risks related to large-scale and complex specialty contracting projects impacting profitability.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026